Translating genomic profiling to gastrointestinal cancer treatment

Area of Science:

• Genomics and Molecular Biology
• Oncology
• Pharmacogenomics

Background:

• Next-generation sequencing (NGS) provides rapid, cost-effective, and accurate whole-genome sequencing.
• Molecular profiling identifies distinct cancer subtypes, enabling personalized treatment strategies.
• Gastric and colorectal cancers are classified into four molecular subtypes; esophageal cancer classification is ongoing.

Purpose of the Study:

• To summarize current gastrointestinal cancer treatment options based on genomic profiling.
• To discuss the role of molecular subtypes in guiding targeted therapy selection.
• To explore future directions for individualized cancer treatment.

Main Methods:

• Review of existing literature on genomic profiling in gastrointestinal cancers.
• Analysis of molecular subtypes identified through whole-genome sequencing.
• Correlation of specific molecular features (e.g., HER2, KRAS, NRAS, BRAF) with treatment responses.

Main Results:

• Identification of HER2 expression in gastric adenocarcinoma and KRAS, NRAS, BRAF mutations in colon cancer are critical for treatment decisions.
• Molecular subtypes are increasingly recognized as essential for tailoring therapy in gastrointestinal malignancies.
• Genomic profiling facilitates the discovery of actionable molecular features.

Conclusions:

• Genomic profiling is fundamental for understanding and classifying gastrointestinal cancers.
• Personalized therapy based on molecular subtypes is essential for overcoming treatment resistance and improving prognosis.
• Continued research into genomic profiling will drive advancements in individualized gastrointestinal cancer treatment.